Search - tctmd.com

Displaying 361 - 380 of 484

Sort: Relevancy | Date

Presentation TCT 2014

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Giulio G. Stefanini

September 14, 2014

Presentation TCT 2014

Evaluation and Treatment of Stent Thrombosis: From Acute Patency to Long-term Vascular Stability

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Ron Waksman

September 14, 2014

Presentation TCT 2014

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

Presenter: Pieter C. Smits

September 14, 2014

Presentation TCT 2014

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

Presenter: Evald H. Christiansen

September 14, 2014

Presentation TCT 2014

Follow the Data: Fluorinated Polymer-Based DES are Safer than Bioresorbable-Based DES!

Presenter: Hyo-Soo Kim

September 14, 2014

Presentation TCT 2014

Bioresorbable Polymer-Based DES are the Right Choice to Minimize Stent Thrombosis!

Presenter: Stephan Windecker

September 14, 2014

Presentation TCT 2014

Are Current DES Really Safer Than BMS?

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Tullio Palmerini

September 14, 2014

Presentation TCT 2014

Beyond the Guidelines: What Is the Optimal Duration of DAPT After Metallic DES Implantation, and Is It Device Specific?

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Marco Valgimigli

September 14, 2014

Presentation TCT 2014

Prevention of Stent Thrombosis: Devices, Pharmacology, Technique, Patients, and More

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Lorenz Raber

September 14, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

Case #1: Retroperitoneal Hematoma and External Iliac Artery Thrombosis After Primary PCI

Presenter: Mahmoud Hashemian, Ajay J. Kirtane, Mohammad Ali Ostovan, Hrvoje Pintaric

September 14, 2014

Presentation TCT 2014

Complication Case #2: Stent Thrombosis and Abrupt Closure

Presenter: Run-Lin Gao, Martin B. Leon, Gregg W. Stone, Qi Zhang

September 13, 2014

Presentation TCT 2014

Restenosis and Stent Thrombosis

Presenter: George D. Dangas, Kevin J. Croce

September 13, 2014

Presentation TCT 2014

NIRS for Identifying Vulnerable Plaque Prior to Coronary Thrombosis

Presenter: Gary S. Mintz, Patrick W. Serruys, Ryan D. Madder, Akiko Maehara

September 13, 2014

Presentation TCT 2014

OCT for Identifying Vulnerable Plaque Prior to Coronary Thrombosis

Presenter: Gary S. Mintz, Patrick W. Serruys, Ryan D. Madder, Yuji Ikari

September 13, 2014

Presentation TCT 2014

HORIZONS-AMI and EUROMAX Stent Thrombosis: Predictors of Stent Thrombosis and Risk for 30-Day Mortality After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

Presenter: Patrick W. Serruys, George D. Dangas

September 13, 2014

Presentation TCT 2014

TCT 644: Stent Thrombosis Rates of the Biodegradable Polymer, Biolimus-Eluting Stent Versus the Durable Polymer, Everolimus-Eluting Stent in All Comers Undergoing PCI: A Pooled Analysis of the COMPARE II and NEXT Trials at 1 Year

Presenter: Valentin Fuster, Pieter C. Smits

September 13, 2014

Presentation ESC 2014

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Presenter: Christoph Varenhorst

August 30, 2014

Presentation

Endeavour ZES Reduces Stent Thrombosis and Improves Outcomes Compared with Cypher SES

Presenter: W. Wijns

August 22, 2014

Presentation

SYNTAX Score and the Risk of Stent Thrombosis After PCI in Patients with NSTE-ACS

Presenter: M. Yadav

July 08, 2014

Advertisement

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

Evaluation and Treatment of Stent Thrombosis: From Acute Patency to Long-term Vascular Stability

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

Follow the Data: Fluorinated Polymer-Based DES are Safer than Bioresorbable-Based DES!

Bioresorbable Polymer-Based DES are the Right Choice to Minimize Stent Thrombosis!

Are Current DES Really Safer Than BMS?

Beyond the Guidelines: What Is the Optimal Duration of DAPT After Metallic DES Implantation, and Is It Device Specific?

Prevention of Stent Thrombosis: Devices, Pharmacology, Technique, Patients, and More

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Case #1: Retroperitoneal Hematoma and External Iliac Artery Thrombosis After Primary PCI

Complication Case #2: Stent Thrombosis and Abrupt Closure

Restenosis and Stent Thrombosis

NIRS for Identifying Vulnerable Plaque Prior to Coronary Thrombosis

OCT for Identifying Vulnerable Plaque Prior to Coronary Thrombosis

HORIZONS-AMI and EUROMAX Stent Thrombosis: Predictors of Stent Thrombosis and Risk for 30-Day Mortality After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

TCT 644: Stent Thrombosis Rates of the Biodegradable Polymer, Biolimus-Eluting Stent Versus the Durable Polymer, Everolimus-Eluting Stent in All Comers Undergoing PCI: A Pooled Analysis of the COMPARE II and NEXT Trials at 1 Year

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Endeavour ZES Reduces Stent Thrombosis and Improves Outcomes Compared with Cypher SES

SYNTAX Score and the Risk of Stent Thrombosis After PCI in Patients with NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content